Clot-removing treatments for sudden blood clots in the lungs, observed in Nordic hospitals
Observes catheter procedures and alteplase in adults with pulmonary embolism.
Key facts
- Who runs it
- Sahlgrenska University Hospital
- Where
- Denmark and Sweden13 sites in 2 countriesChoose a country to see its sites
- Trial code
- Registry title
- Reperfusion Treatment in Acute Pulmonary Embolism
- Status
- Recruiting
- People taking part
- 220 people, planned
- Started
- 1 Apr 2025
- Expected to end
- 1 May 2029
- Type of study
- Observational, 2 groups
- Treatments tested
- Catheter directed intervention, any device
- Alteplase
- Record updated
- 21 January 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a confirmed sudden blood clot in the lungs (acute pulmonary embolism). They must be planned for, or have had, catheter treatment or clot-dissolving drugs through a vein.
- Age
- 18 years and older
- Sex
- All sexes
- Disease stage
- Acute pulmonary embolism confirmed by a scan (CTPA, angiography or scintigraphy). Pregnant women can also join.
- Earlier treatment
- People must be planned for, or have received, catheter directed intervention or systemic thrombolysis (clot-dissolving drug through a vein).
Main reasons for not taking part
- Taking part right now in an interventional trial of catheter directed treatment
- Surgery to remove the clot (surgical embolectomy) as the first treatment to restore blood flow
The registry criteria, word for word
Show all 4 criteriaShow less
Who can take part
- All adult patients (≥18 years), including pregnant women, with verified (CTPA, angiography or scintigraphy) acute pulmonary embolism who are planned for, or have received, treatment with catheter directed intervention or systemic thrombolysis
- Informed consent (for patients who do not survive before informed consent can be obtained, a waiver of consent applies)
Who cannot take part
- Surgical embolectomy as primary reperfusion treatment
- Ongoing enrolment in interventional catheter directed intervention trial
This trial has no sites in United States.
It has sites in 2 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
International guidelines recommend immediate reperfusion with systemic thrombolysis (ST) as first-line treatment in high-risk pulmonary embolism (PE). The therapy improves hemodynamics and overall survival but is also associated with a significant risk of severe bleeding. Catheter-directed intervention (CDI) is recommended as an alternative reperfusion therapy in high-risk PE when ST is contraindicated or has failed, as well as in patients who deteriorate or fail to improve during anticoagulation (AC) treatment. Despite lack of high-quality evidence and randomized studies between CDI and standard care, the use of CDI is spreading rapidly in high-risk PE and in less severe PE not fulfilling current treatment criteria.
The 2 groups in the trial
- Catheter-directed intervention
Catheter-directed intervention, any device
Treatment: Catheter directed intervention, any device
- Systemic thrombolysis
Intravenous thrombolysis with tissue-type plasminogen activator (tPA)
Treatment: Alteplase
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Reperfusion Treatment in Acute Pulmonary Embolism: A Multicenter Observational Study in the Nordic Countries
- Plain-language title
- Clot-removing treatments for sudden blood clots in the lungs, observed in Nordic hospitalsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Publications
- Record updated
- 21 January 2026